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ABSTRACT
Inflammatory bowel disease patients have higher rates of depression and anxiety
compared to other diseases and the general population, which can lead to a lower quality
of life. There is a critical need to investigate treatments for mental health in patients with
inflammatory bowel disease. Cognitive behavioral therapy is widely studied and has
proven effective in improving depression. There are no randomized controlled trials
comparing early psychotherapeutic intervention with standard of care for this population.
We hypothesize that early initiation of cognitive behavioral therapy will reduce
depression and anxiety severity and improve quality of life in newly diagnosed
inflammatory bowel disease patients compared to standard care. Participants will be
randomized to either video therapy or standard care for 12 weeks. Findings may inform
the need for early mental health intervention in the disease management of this
population.

v

CHAPTER 1: INTRODUCTION
1.1 Background
Inflammatory bowel disease (IBD) is a chronic relapsing-remitting illness of the
gastrointestinal tract that mainly consists of ulcerative colitis (UC) and Crohn’s disease
(CD). The incidence and prevalence of IBD in the United States and worldwide has
steadily increased over time.1,2 Its course and prognosis can be uncertain and
unpredictable; no conclusive cure exists. Disease activity is classified as mild, moderate,
severe, or fulminant based on combined clinical and endoscopic assessments.3 Physical
symptoms include diarrhea, bowel spasms, feces containing blood or mucus, pain, and
fatigue.4 Treatment is often life-long and associated with undesired side effects and
complications.5 Relapses can be intense and affect daily functioning.6 Those with
moderate-severe IBD can experience complications including abscesses and fistulas that
cause chronic pain and severely impact quality of life.5 Current treatment for moderatesevere IBD includes biologic therapy; however, there remain appreciable rates of primary
non-response, loss of response, or adverse reactions.2 Overall, IBD symptoms and
treatments affect patients’ physical, mental, and social well-being, which encompasses
their health-related quality of life (HRQOL).7 Because this disease typically appears
early in life, between ages 15 and 298, with no contribution to a shortened life span,
treatment early in the disease course is crucial.9
Rates of depression and anxiety are higher among those with UC and CD as
compared to other diseases and the general population. One systematic review found that
depression was as high as 21.2% in patients with IBD vs 13.4% in healthy controls.10
Other clinical studies have shown the prevalence of anxiety/depression symptoms to be
1

about 30% in IBD cohorts compared to the general population.11 Additionally, there are
higher rates of anxiety and depression in the early period around IBD diagnosis9 and in
those with active disease compared to those in remission.12 Lastly, there are higher rates
of hospitalization and disease severity in IBD patients with depression/anxiety compared
to those without.13 These higher rates of psychiatric disorders are similar to those with
rheumatoid arthritis14 and diabetes15, and may be higher compared to those with heart
failure.16 One controlled study investigated the need for psychological interventions in
patients with IBD compared to rheumatoid arthritis (RA), another chronic inflammatory
disorder.17 Stepwise logistic regression analysis showed an independent association
between inflammatory bowel disease patients who expressed a need for psychotherapy
and short disease duration (< 2 years) (p = 0.005).17 In this study, a significantly higher
percentage of patients with IBD (31%) expressed a need for psychological intervention
when compared to patients with RA (13%; p < 0.001). This shows the increased need for
psychotherapeutic intervention in the IBD population with short disease duration
specifically.
A bidirectional relationship exists between depression/anxiety and IBD. The
severity of IBD inflammation and its associated symptoms can lead to
depression/anxiety, while depression/anxiety can exacerbate inflammation.18 In four large
studies, pooled data showed that adults with active IBD had much higher rates of anxiety,
66.4%, compared to 22% in adults with inactive IBD.10 Similarly, in five studies, the
pooled rate of depressive symptoms during active IBD was 34.7% compared to 19.9% in
inactive IBD.10 Those with untreated and/or unrecognized psychologic disorders are at
risk for increased hospitalizations and disease flares19, lower compliance with treatment,
2

and increased healthcare costs. Despite high levels of depression and anxiety in IBD
patients, one study showed that many experiencing psychiatric symptoms were
undertreated.20
While the impact of depression and anxiety on the course of IBD is known, the
research for depression and anxiety treatments is limited by the number of studies and
low methodological quality.21,22 Treatment for depression and anxiety in IBD patients is
usually pharmacologic therapy or psychotherapy. One systematic review found that the
use of antidepressants was effective in improving disease activity, IBD symptoms, and
depression, but these findings were limited due to lack of randomized controlled trials
and small sample sizes.11 Additionally, antidepressants have potential adverse side
effects.11 The same systematic review reported patient satisfaction with psychotherapy.11
Psychotherapeutic interventions may be beneficial in IBD by not only improving quality
of life and mental health, but also by reducing inflammation.23 A 2019 systematic review
showed that mindfulness interventions had significantly long-term improvements on
depression.21 Another systematic review showed that newly diagnosed IBD patients have
the greatest need for early psychotherapy intervention.24 Generalizability of results has
been limited by past samples excluding those with moderate-severe IBD25-27 and those
with moderate-severe depression.28
Cognitive behavioral therapy is a psychotherapeutic intervention that is welldeveloped and has been found to enhance quality of life while reducing psychological
distress.5,29 A previous review concluded that patients with IBD are most likely to benefit
from psychological therapy if it is individualized, holistic, targets psychological
symptoms and individual stressors, and is CBT-based.30 CBT intervention focuses on
3

directly targeting symptoms, reducing distress, re-evaluating thinking and promoting
helpful behavioral responses.24 The duration of CBT varies, often ranging between 10
and 20 sessions.31 CBT has been found to be effective in people with other chronic
illnesses such as chronic obstructive pulmonary disease32, diabetes33, and cancer34.
Among adult patients with IBD who report comorbid psychiatric symptoms or low
quality of life, research suggests that CBT can be effective for these individuals.30,35 One
2013 study shows evidence that CBT improves mental health in patients with IBD both
immediately following the interventions and at > 6 months of follow-up.35 Research has
also suggested that CBT is likely more effective for those with higher baseline depression
and anxiety severity due to the larger margin for symptoms reduction compared to a
relatively low baseline severity.36,37 However, limitations of traditional CBT include
travel to the therapist’s office, constraints with the therapist’s schedule, and long waiting
lists.36
Many people that require treatment for depression may not receive it due to poor
accessibility or affordability of the available options.36 Using online interventions to
deliver psychotherapy can solve this problem. A 2018 systematic review looked at the
efficacy and economic value of online cognitive behavioral therapy (oCBT) for major
depressive disorder.38 The format of oCBT varies, but it mostly entails self-help guidance
with the use of written materials, audio, or video files, guided by a therapist via email or
phone call engagement.39 There are clear indications that the presence of a therapist
guiding the patients and providing feedback is important for adherence and outcome.39
There is also evidence that guided oCBT is equally as effective as traditional CBT in
improving depressive symptoms.36 Although this review included only those with
4

diagnosed major depressive disorder, the results strongly suggest that therapist-guided
oCBT can reduce symptom severity.
In addition to studying the effectiveness of CBT, the acceptance of CBT should
be considered. Patient experiences with blended video- and internet-based psychotherapy
intervention has been studied in adults suffering from major depressive disorder.40 This
intervention consists of four core components: (1) a face-to-face diagnostic interview (2)
video-based synchronous therapy sessions (VTS) (3) online self-help treatment modules
(OTM) (4) online and smartphone based monitoring of behavior and symptoms (BSM).40
In a study evaluating the patient’s experience with blended video- and internet-based
CBT service in routine care, the treatment was tailored specifically to each patient
directed by the therapist. A disadvantage of internet based guided self-help intervention is
tailoring it towards individuals, but the addition of video-based synchronous therapy
sessions helps overcome this issue. Patients found this blended therapy equal or superior
to traditional face-to-face therapy.40 The many advantages of online CBT are that patients
can schedule and receive therapy from any location with Internet access, patients with
physical limitations can receive care, social stigma is lessened or eliminated, and
introverted patients may be more open and receptive to treatment.41 The combination of
telemedicine with traditional cognitive behavioral therapy is a feasible, affordable, and
effective treatment.
During the Covid-19 pandemic, telemedicine consultations (video/audio) proved
to be a feasible and acceptable option for care of IBD patients.42 Patients can undergo a
video consultation via a mobile app or video-based digital platform. This allows patients
to receive care without travel limitations. One study reported 60.5% percent of IBD
5

adults met criteria for at least moderate depression, anxiety, and/or stress during the
pandemic and more than two-thirds of those with pre-existing diagnoses reported
worsening symptoms due to the psychological impact of the pandemic.43 During this
pandemic, people suffering from chronic illnesses have experienced greater distress than
the general population43 which demonstrates the need for mental health treatment in this
population.
There is not yet an established first-line treatment for moderate-severe depression
and anxiety in adults with moderate-severe inflammatory bowel disease. Newly
diagnosed patients demonstrate the greatest need for psychotherapy and early
intervention.24 Yet several barriers exist, such as social stigma, financial burden, lack of
mental health professionals trained in working with IBD patients, and lack of timely
referrals to a mental health specialists.24 Additionally, CBT has a greater impact for those
with higher scores of anxiety and low mood at baseline.37 With today’s era largely
shifting to telemedicine, video-based, therapist-guided cognitive behavioral therapy is a
feasible, cost-effective, and accessible treatment option that has proven to improve
depression and anxiety.36,44-46 This form of therapy may be more accessible to our IBD
population who suffer from moderate-severe disease symptoms and moderate-severe
psychological symptoms at baseline.36 With proper equipment, video-based, therapistguided cognitive behavioral therapy may increase adherence and remain a similar
experience to traditional face-to-face CBT. Thus, this psychotherapeutic intervention
could give more newly diagnosed IBD adults a more accessible option to improve their
quality of life.
1.2 Statement of the problem
6

Depression and anxiety independently decrease the quality of life in patients with
IBD. Those with moderate to severe IBD have shown to have higher rates of depression
and anxiety compared to those with mild or inactive IBD. Patients are recommended to
seek treatment after mental health symptoms arise; however, studies show a low
proportion of patients have access to psychiatric consultation and psychotherapy, and
studies found a low rate of psychiatric referrals among IBD patients.47,48 Adults with
moderate-severe depression at baseline have experienced benefits from CBT.36,37
Research has shown mixed results on the effectiveness of cognitive behavioral therapy in
changing disease activity27,37 and mental health/quality of life in adults with IBD.49,50
Multiple gaps of literature have been identified: 1. Newly diagnosed IBD patients present
with the greatest need for psychotherapeutic intervention, but there is a lack of efficacy
trials of CBT in newly diagnosed IBD adults. 2. Prior research studying CBT in adults
with IBD have excluded those with active or moderate-severe IBD disease25-27 when this
subgroup may benefit the most from a psychotherapeutic intervention. 3. Only traditional
face-to-face or self-help computerized CBT RCTs have been conducted in this
population; there is a lack of RCTs using video-based CBT as an intervention in adults
with IBD.
There is a need for more randomized controlled trials (RCTs) comparing the
effectiveness and acceptance of video-based, therapist-guided CBT to traditional face-toface CBT. Because there are many different forms of online/computerized CBT, this
limits generalizability from previous studies to this population. Past RCTs were
underpowered due to low adherence and high attrition to traditional37,51 and even
computerized cognitive behavioral therapy27. The literature needs to extend to an RCT
7

comparing video cognitive behavioral therapy to standard medical care in IBD adults to
add an accessible and non-invasive option in improving mental health and quality of life.
1.3 Goals and Objectives
In this RCT, we aim to investigate the multidimensional effects of video-based,
therapist-guided cognitive behavioral therapy compared to standard medical care in
adults with newly diagnosed moderate-severe inflammatory bowel disease who present
with moderate-severe depressive and/or anxiety symptoms at baseline. Our primary aim
is to prevent a secondary diagnosis of depression and/or anxiety with early initiation of
CBT following new primary diagnosis of IBD in adults. Our secondary aims investigate
if it is conducive to perform video CBT and if CBT affects disease activity. Only adults
with IBD who meet eligibility criteria will be enrolled in this RCT. Participants will be
randomly assigned to one of two groups: video CBT or standard medical care. They will
be followed weekly for 12 weeks and at 3-month follow-up. The main objective is to
observe differences in mean change from baseline in self-reported depression and anxiety
scores as measured by the Hospital Anxiety and Depression Scale (HADS) between
groups. Due to the bidirectional relationship between psychological symptoms and
disease symptoms, we will also assess disease progression and quality of life. Secondary
objectives include: 1. Differences in mean change between groups in quality of life as
measured by the Short Form Survey (SF-12), 2. Differences in mean change between
groups in disease severity as measured objectively by inflammatory markers, consisting
of CBC, ESR, CRP, and fecal calprotectin, and 3. Differences in mean change between
groups in disease severity as measured endoscopically by the Simple Endoscopic Score
for Crohn’s Disease (SES-CD) and the Mayo Score for ulcerative colitis.
8

1.4 Hypothesis
Recently diagnosed moderate-severe IBD adults with moderate-severe depression
and/or anxiety aged 18-40 who are treated with CBT as adjuvant to standard of care will
have a statistically significant decrease in depression and/or anxiety scores as measured
by the HADS scale from baseline to 12-week follow-up in comparison to patients
receiving standard of care, and results will be maintained 3 months after intervention
completion.
1.5 Definitions
Standard medical care: Annual visits with gastroenterologists that may include lab
draws, medication prescriptions, biologic infusions, colonoscopies, and/or endoscopies.
Depression: Feelings of sadness and loss of interest, which stops one from doing normal
activities. A score of greater than > 8 on the HADS.
Anxiety: Feelings of worry, nervousness, or unease, typically about an imminent event or
something with an uncertain outcome. A score of greater than > 8 on the HADS.
Moderate-severe IBD: Measured endoscopically using a Simple Endoscopic Crohn’s
Disease score > 752 for those with CD or a Mayo Full Score > 6 or Mayo Endoscopic
Score > 2 for those with UC.53
Online Cognitive Behavioral Therapy (oCBT): Synonymous with internet cognitive
behavioral therapy (iCBT) for the purpose of this paper. Cognitive behavioral therapy
administered online. The methodology varies, but it typically consists of one-hour weekly
sessions. Sessions differ in the extent to which they provide guidance or support.54
Guidance can include informational and supportive automated emails sent to participants,
brief weekly phone calls from therapists or research assistants providing encouragement,
9

support and clarification of lesson content and homework, or text-based communication
between clients and clinicians.54
Computerized Cognitive Behavioral Therapy: A type of self-help therapy delivered via
the internet. It uses the same techniques as a therapist would in face-to-face CBT.
Video-Based, Therapy-Guided Cognitive Behavioral Therapy: Formatted as traditional
face-to-face CBT but delivered via video-based platform by a therapist.
Hospital and Anxiety Depression Scale (HADS): A self-reported 14-item scale used to
determine the levels of anxiety and depression that a person is experiencing. Each item
on the questionnaire is scored from 0-3. A person can score between 0-21 for either
anxiety or depression.
Simple Endoscopic Crohn’s Disease (SES-CD): A four-component disease activity score
measured during endoscopy that assesses the size of mucosal ulcers, the ulcerated
surface, the endoscopic extension, and presence of stenosis. The score ranges from 0 to
>15.
Mayo Score for Ulcerative Colitis: The most commonly used scoring system for
ulcerative colitis disease activity that assesses stool frequency, rectal bleeding, mucosal
appearance at endoscopy, and physician rating of disease activity.
Short Form Survey (SF-12): A self-reported 12-item survey assessing the physical and
mental health on an individual’s everyday life through eight health domains. It is often
used as a quality-of-life measure. It is a shortened version of the SF-36.
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CHAPTER 2: REVIEW OF THE LITERATURE
2.1 Introduction
A search of relevant medical literature was conducted between August 2020 and
June 2021 using Ovid Medline, EMBASE, PsychINFO, Cochrane, and Scopus. Primary
searches were performed using the combination of MeSH terms “inflammatory bowel
disease,” “Crohn’s disease,” “ulcerative colitis,” “cognitive behavioral therapy,”
“telemedicine,” “psychotherapy,” “depression,” and “anxiety.” Additional search terms
included quality of life, health related quality of life, HRQOL, online cognitive
behavioral therapy, video cognitive behavioral therapy, videoconferencing, and
telemedicine. Articles included in this literature review were written in English with the
exception of one randomized controlled trial written in Spanish and translated to English
due to the results being pertinent to our study. Articles were analyzed for relevancy to our
proposed research study. We analyzed clinical trials, meta-analyses, and systematic
reviews, and examined reference lists of primary articles to search for additional relevant
references for our study.
The literature search and review demonstrate the prevalence of depression and
anxiety in inflammatory bowel disease patients and mixed conclusions about the efficacy
of psychotherapy intervention on this population. No randomized controlled trials have
been conducted using video-based CBT as an intervention in adults with IBD. The review
was expanded to include video-based CBT in other diseases, so we could thoroughly
review previous methodology necessary to properly compose our study. Although other
modes of CBT have been widely studied in IBD patients, there is much to be learned
regarding its efficacy on those recently diagnosed with increased anxiety and depression
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at baseline. Additionally, there is much to be learned regarding the efficacy of videobased CBT in this population.
2.2 Review of Empirical Studies
2.2.1 Depression and Anxiety in Adults with Inflammatory Bowel Disease
Multiple studies have demonstrated the prevalence of depression and anxiety in
patients with IBD. An observational study evaluated the prevalence of depression and
anxiety in patients with IBD compared to healthy volunteers.1 Participants took selfassessment tests for depression, using the Patient Health Questionnaire-9 (PHQ-9), and
anxiety, using the Symptom Checklist Anxiety Scale (SCL-A20). Results showed a
higher prevalence of depression (34.3% vs 5%, p < 0.0001) and a higher prevalence of
anxiety (18.6% vs 2%, p = 0.0002) in IBD patients compared to controls.1 Another study
determined the prevalence of depression in people with IBD from two nationally
representative Canadian self-report surveys.2 Logistic regression analysis showed that the
odds of having depression among those with IBD compared to the general population
were highest in those ages 20-49 (ages 20-29: OR 9.14, p < 0.001; ages 30-39: OR 11.79,
p < 0.001; ages 40-49: OR 9.70, p < 0.001), while the odds were lowest among ages 7079 (OR 1.33, p < 0.001 ).2 Rates of depression from both survey samples were similar
(16.3% and 14.7%) and higher than the general Canadian population (5.6%).2 A
population-based cohort study looking at IBD adults compared to matched community
samples in the US and New Zealand found that the majority of participants had a
psychiatric disorder preceding their diagnoses of IBD (p = 0.001).3 Episodes of
depression and anxiety are more likely to occur during periods of acute stress; the period
around IBD diagnosis can be especially stressful.3
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A few studies have demonstrated that those with higher IBD disease activity have
higher levels of anxiety and depression compared to IBD patients in remission and to the
general population.4-6 In a retrospective study, researchers used logistic regression
analysis to identify risk factors for depression in patients with inflammatory bowel
disease.4 Clinical disease activity was an independent risk factor for depression in CD (p
= 0.001). 70% of patients with CD in clinical remission had no risk of depression, while
75.6% of patients with active CD had either mild depression or were at risk for major
depression. There was no independent risk factor identified for those with UC.
Additionally, there was a negative correlation between health-related quality of life, as
measured by SF-12 mental sub-scores, and depression, as measured by PHQ-9, in both
patients with CD and UC (CD: p < 0.001; UC: p < 0.001). Another study compared
anxiety and depression of CD and UC patients with chronic liver disease patients and the
general population, controlling for sociodemographic and medical variables with ageand sex-matched controls.7 Analysis of variance (ANOVA) showed the frequency of a
probable mental disorder was 49.1% in those with moderate/severe disease activity
compared to 11.3% in IBD patients in remission (p < 0.001).7
One study specifically examined if inflammatory bowel disease patients with
anxiety/and or depressive symptoms receive the care they need and if clinical and sociodemographic variables are associated with those symptoms.8 IBD patients scored
significantly higher on the anxiety (p = 0.00) and depression (p = 0.00) subscales of the
HADS, with small effect sizes of 0.29 and 0.32 respectively, and significantly lower on
the physical health component (PCS) (p = 0.00) and the mental health component (MCS)
(p = 0.00) of the quality of life scale (SF-12), with moderate effect sizes of 0.70 and 0.58
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respectively, compared to the general population.8 Of the 95 participants (42.6%) who
indicated high levels of anxiety and/or depression, only 17 participants (17.9%) received
mental help in the preceding four weeks. Only 20 participants (21.1%) who indicated
high levels of anxiety/depression were being treated with psychotropic medication. Using
multivariate logistic regression analysis, factors associated with high levels of anxiety
(HADS anxiety subscale > 8) were active disease (p = 0.024) and Crohn’s disease (p =
0.029).8 The only factor associated with high levels of depression (HADS depression
subscale > 8) was active disease (p = 0.008).8
The psychological impact of the Covid-19 pandemic on IBD adults should be
considered. There have been few survey studies looking at this impact. One crosssectional survey investigated the influence of Covid-19 on HRQOL of IBD patients,
controlling for disease activity.9 The study included two samples of 195 IBD patients
recruited from an outpatient setting prior to the Covid-19 outbreak and 707 IBD patients
recruited through an online survey during the highest pandemic peak (March to May
2020). Results showed large effect sizes; patients with active IBD showed higher
psychological distress, as measured by HADS (d = 0.34), and lower disease-specific
HRQOL, as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) (d >
0.50).9 Hierarchical regression analysis determined that the setting (pre-Covid-19
outbreak vs. during lockdown) played a very small factor in IBDQ variance (p < 0.001),
demonstrating that psychological distress and quality of life are impaired regardless of
the pandemic. This study is limited due to its cross-sectional nature and therefore,
inability to make a causal inference. Another study done in Portugal explored the
pandemic’s effect on disease and psychological outcomes of people with IBD.10 Anxiety
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and depressive symptoms, measured by HADS, were studied in 124 Portuguese
participants ages 18-64 years old. Correlation analyses showed a significant association
between IBD symptoms and fear of contracting Covid-19 (p < 0.01).10 Regression
analyses showed anxiety significantly accounted for IBD symptom perception (p =
0.022), but depression did not.10 More frequent symptoms may lead to increased hospital
visits for IBD patients, which may prove challenging for those fearful of contracting
Covid-19. This study showed that the fear of contracting Covid-19 was the most relevant
variable for depressive symptomatology and anxiety severity, which demonstrates the
pandemic may have significant contributions to outcomes in this population. Further
longitudinal studies are needed to investigate the long-term effects of the Covid-19
pandemic on this population.
2.2.3 Interventions for Depression and Anxiety in People with Inflammatory Bowel
Disease
Treatment for depression and anxiety in IBD consists of psychotropic medication
and psychotherapy.11 Currently, there is no gold standard method for treatment and
management of depression and anxiety in IBD. The most widely used pharmacologic
agents are tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors
(SSRIs), such as citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, and a
serotonin norepinephrine reuptake inhibitor (SNRI), such as venlafaxine).11,12
Antidepressants are recommended for patients with moderate to severe symptom severity
with a reduced quality of life.12 TCAs are effective in chronic pain syndromes, but
adverse effects include sedation, anticholinergic effects, insomnia, nightmares, and
agitation.12 SSRIs improve symptoms of anxiety and depression, but adverse effects may
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be agitation, insomnia, sexual dysfunction, nausea, or diarrhea.12 SNRIs seem to help
reduce pain in pain-related conditions, with less adverse effects than TCAs.12 IBD
patients take more medications than the healthy population, such as antibiotics (OR =
4.01, 95% CI: 3.57-4.51), proton pump inhibitors (OR = 3.90, 95% CI: 3.48-4.36), and
nonsteroidal anti-inflammatory analgesics (OR = 1.17, 95% CI: 1:07-1.28).11
Pharmacologic treatment can be effective but poses adverse effects, concern for
tolerance, problems when tapering off medications,11 cost, fear of becoming dependent13,
and additional medication burden.
The most widely used psychological treatment for depression and anxiety in IBD
patients is cognitive behavioral therapy.11 CBT has shown to be most effective in
reducing symptoms and relapse rates out of all psychotherapeutic interventions.14 CBT is
a well-developed intervention proven to improve quality of life and decrease
psychological distress.11 It has shown positive effect in individuals with other chronic
somatic illnesses, such as chronic obstructive pulmonary disease15, diabetes16, and
cancer.17 There has been mixed evidence on the effectiveness of CBT in those with IBD,
but research has shown consistent benefits for those with anxiety and depression
symptoms.18 One systematic review found that CBT is indicated for high-risk subgroups,
such as those with comorbid psychiatric conditions or elevated stress.19 CBT as an
intervention in IBD patients has been studied in various methods of delivery, such as
traditional face-to-face sessions20, both face-to-face and computerized 21,22, computerized
CBT,23 blended face-to-face and telephone/Skype with a therapist24,25, group sessions26,
and various types, such as self-help CBT27, mindfulness-based28, and diseasespecific.29,30 One study randomized adults with IBD who self-reported fatigue to either an
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8-week CBT intervention (one 60-min session and seven 30-min telephone/Skype
sessions with a therapist) or a control group.25 There was an improvement in quality of
life (IBDQ) in both groups. The intervention group showed greater change between
baseline and 12 months compared to the control group (MD = 8.43 [CI = -1.74, 18.60]),
with a between group effect size of 0.98 (CI = -2.10, 0.23).25 Although this study
measured baseline and 3 month follow-up means and standard deviations of anxiety and
depression, these outcomes were not included in their statistical analysis. This study was
also limited due to a small sample size, lack of generalizability due to recruitment from
one tertiary referral center, and self-reporting of disease activity.
In addition to CBT, other non-pharmacologic interventions, such as mindful based
stress reduction (MBSR)31, Breath—Body—Mind Workshop (BBMW)32, guided
imagery and relaxation33, solution-focused therapy (SFT)34, yoga35, and gut-directed
hypnotherapy36 have been studied in adults with IBD. A recent meta-analysis of 10 RCTs
investigated the effectiveness of non-pharmacological interventions on reducing anxiety,
depression, and disease specific quality of life in adults with IBD compared to control
groups.37 It showed the pooled standardized mean differences (SMD) for the effect of
non-pharmacological interventions on anxiety was -0.28 (p = 0.004) and the pooled SMD
for the effect of non-pharmacological interventions on depression was -0.22 (p = 0.025),
suggesting that this intervention significantly reduced anxiety and depression among
adults with IBD. Non-pharmacologic interventions prove to be an option for management
of anxiety and depression among adults with IBD; all providers should discuss these
treatment options with patients in this population. 37
2.2.4 Benefits of Cognitive Behavioral Therapy
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Traditional face-to-face CBT has been widely studied and proven effective in
treating depression and anxiety in the general population.38 This traditional method
requires the individual to work face-to-face with their therapist to identify, challenge, and
evaluate the thoughts that maintain the depressive mood.13 A review of the benefits of
CBT in the primary care setting showed a statistically significant treatment effect (48
studies, 157 effect sizes, d = 0.474, p < 0.001).38 CBT has also demonstrated its use in
adults with other chronic, debilitating diseases. A randomized controlled trial study
investigated the effectiveness of CBT when applied to patients with relatively early
rheumatoid arthritis (disease duration <8 years). Intention-to-treat results demonstrated
beneficial effects of CBT in the intervention group compared to the control (standard
medical care) group. Univariate test results looking at a time x group interaction effect
demonstrated depression significantly decreased in the CBT condition at post-treatment
and follow-up (t = 3.02, p <0.01 and t=3.10, p < 0.01, respectively) compared to the
control group (t = -0.57, p = 0.58 and t = -1.23, p = 0.23, respectively).39 CBT
intervention in early IBD population has yet to be studied; however, rheumatoid arthritis
is also a chronic disabling disease which makes the two diseases comparable. A
limitation in the methodology remains the same from past CBT studies: 43% of eligible
participants refused to participate due to practical concerns, such as traveling distance
and scheduling difficulties with participating face-to-face.39
During the Covid-19 pandemic, there has been a shift in CBT delivery from
traditional face-to-face to online CBT (oCBT). For the purpose of this literature review,
we included studies that utilized videoconferencing psychiatric treatment, digital CBT,
internet-delivered, and therapist-supported/guided online CBT to improve depression and
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anxiety. Since this intervention has not been widely studied in IBD patients, we studied
the efficacy of this intervention in other chronic disease populations. A review of the
clinical efficacy and economic evaluation of oCBT vs. face-to-face CBT for major
depressive disorder found that oCBT is likely more effective for those with higher
baseline severity due to the larger margin for symptom reduction, compared to those with
lower baseline severity.13 Meta-analysis found oCBT superior and produced a significant
improvement in depressive symptoms relative to comparator treatments (p < 0.0001).13
One randomized controlled trial investigated the effectiveness of ten 55 minute
sessions of individual CBT delivered online in real time by a therapist compared to usual
care for adults aged 18-75 with depression in primary care.40 The primary outcome was
recovery of depression, measured by a Beck’s Depression Index (BDI) score <10 four
months after randomization. Results showed participants in the intervention group were
more likely to achieve depression recovery at 4 months compared to the control group (p
= 0.001).40 The benefit from the intervention was also maintained at 8 month follow-up
(p = 0.023).40 After adjustment for baseline imbalance, the intervention demonstrated
improvement in depressive symptoms (p = 0.0002), health status (p = 0.045), and quality
of life (p = 0.024) at 8 month follow-up with an effect size of 0.70.40 The study reported
greater benefit of online, therapist-guided CBT for those with severe symptoms at
baseline than those with mild depression; although, the study did not provide the data. It
should be noted that participants in the intervention group were more likely to be taking
antidepressants at follow-up than those in the control group. However, these differences
were small and adjustment for them had no effect on the comparisons for recovery at
either follow-up.
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The efficacy and feasibility of psychiatric consultations via videoconferencing
compared to face-to-face (F2F) for treatment of depression has been studied. In one
study, 107 adults with mild depression were randomly allocated into a videoconferencing
intervention group or an F2F group consisting of monthly follow-up consultations with a
psychiatrist for 5 months.41 Outcome measures of depression severity, mental health
status, medication course, relapses, satisfaction with treatment, therapeutic relationship,
treatment adherence, and medication adherence were assessed at baseline, 6-, and 12month follow-up. ANOVA revealed both groups showed a significant decrease in
severity of depression (videoconferencing: p < 0.001, F2F: p = 0.001) and significant
increase in mental health status (videoconferencing: p = 0.02, F2F: p = 0.01) over the
study period. There were significantly more dropouts in the F2F group than in the
videoconferencing group at 6 months (p = 0.04).41 While there were still more dropouts
in the F2F group at 12 months, this difference did not remain significant. This study
showed greater improvement in depression severity among videoconferencing compared
to face-to-face. However, this study was limited because groups were not balanced with
regard to depression severity; the videoconferencing group had a higher mean score
(7.92) vs. the F2F group mean score (6.19) at baseline. This limits generalizability
because this group had greater potential to decrease in score. While investigators
controlled for the same psychiatrists to deliver F2F and videoconferencing consultations,
possible bias from personal method preference could have influenced outcomes.41
Although this study did not investigate CBT specifically, the efficacy of
videoconferencing for psychiatric treatment can be applied to CBT.

24

In addition to CBT being studied in those with depression, it has also been studied
in those with moderate to severe symptoms of generalized anxiety disorder (GAD). One
study compared digital CBT to waitlist control in patients with a mean age of 30.9 with
moderate to severe symptoms of GAD. Digital CBT was a personalized 6-week CBT
program delivered via smartphone that involved a virtual therapist. Results showed a
statistically significant reduction in anxiety scores in the digital CBT group compared to
the waitlist control group at mid-intervention (p < 0.001), post-intervention (p < 0.001),
and follow-up (week 10) (p < 0.001).42 It should be noted that this virtual therapist was
not a live therapist interacting with the patients, making this platform more self-help
based. It is difficult to generalize the results of these studies with the various
interventions used, but findings show an overall benefit of CBT in improving depression
and anxiety symptoms in adults.
2.2.5 Cognitive Behavioral Therapy as an Intervention for Adults with Inflammatory
Bowel Disease
Multiple studies have investigated the use of cognitive behavioral therapy as an
intervention for depression and/or anxiety in adults with inflammatory bowel disease.
Several reviews have investigated the impact of psychotherapy on biopsychosocial
outcomes for people with IBD and have found mixed results.18,43-45 However, a Cochrane
meta-analysis of RCTs suggested that psychotherapy may benefit IBD adults in either
active or quiescent disease, if a certain degree of emotional distress is present.44 A
limitation of this review was that 19 out of 20 studies included IBD adults without
distress at baseline, which means there was less potential for treatment effects. Results of
past RCTs that found CBT had no effect on mental health were limited due to high
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attrition, low adherence, small sample sizes, or low disease burden at baseline. 22,46 There
have been RCTs that investigated the benefits of CBT on those with increased
psychological symptoms at baseline; these studies will be discussed here.
First, one 2007 study demonstrated the overall positive effect of CBT on adults
with IBD. A randomized controlled trial conducted in Spain investigated the effect of 10week, 2-hour weekly group sessions of face-to-face CBT on anxiety and depression in
IBD adults > age 18.26 Participants were randomized into the intervention group or the
wait-list control group. Exclusion criteria included those in the active phase of the disease
at the beginning of the intervention or those who indicated indices of severe
psychopathology in baseline questionnaires. Outcomes were measured by the 90
Symptom Questionnaire (SCL-90-R), BDI, and HADS. Friedman’s nonparametric test
was used to analyze differences in each of the variables in the different experimental
phases. Comparative analysis between groups was determined using the Eta correlation
coefficient. There was a statistical improvement in anxiety at 3 months (p = 0.001), 6
months (p = 0.01), and 12 months (p = 0.008) and in depression at 3 months (p = 0.0001),
6 months (p = 0.02), and 12 months (p = 0.01) compared to the control group.26 This
study demonstrated that CBT had significant improvement in all emotional variables that
was maintained throughout follow-up. However, limitations of the study include
excluding those with active disease and with severe symptoms of anxiety or depression.
This limits generalizability to the IBD population who may most benefit.
One pilot study looked at the effect of adding CBT to standard treatment
compared to standard therapy alone in prolonging remission in IBD.21 Adult IBD patients
in remission were randomized to a face-to-face/online CBT group or standard care (SC).
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Eligible patients were randomized in a 2:1 proportion (experimental vs. control) in
anticipation of difficulty recruiting the experimental arm due to large participation
burden. The CBT arm was divided into two subgroups, F2F and online but treated as one
for the main analysis. Those who could not commit to the time or travel were offered the
online therapy option. The F2F group underwent 10 weekly two-hour sessions at the
hospital delivered by a psychologist, while the online CBT group received sessions of
similar length online that were self-directed. Outcomes included: 1. IBD remission,
measured by the Crohn’s Disease Activity Index (CDAI) or the Simple Clinical Colitis
Activity Index (SCCAI), 2. mental health status, measured by the Hospital Anxiety and
Depression Scale (HADS), and 3. health-related quality of life (HRQOL), measured by
the Short Form 36 Health Status Questionnaire (SF-36). The HRQOL questionnaire was
broken down into physical and mental component scores. Disease activity was also
measured using blood tests: CRP, hemoglobin (HB), platelet, and white cell count
(WCC). The primary outcome of this study was IBD remission at 12 months (CDAI
score of <15 or the SCCAI score of >3 and confirmed by the treating physician). Two
models were constructed to measure the effectiveness of the intervention. Model 1
included time and group variables and a time-group interaction variable and adjusted for
the outcome variable at baseline. Model 2 adjusted for sex and age. The p value of less
than .05 was considered statistically significant.
Multivariate analysis showed CBT did not significantly change disease activity at
12 months (CD, p = 0.669; UC, p = 0.549) adjusting for baseline. However, at the
univariate level, CBT significantly improved mental quality of life (p = 0.013),
depression (p = .018), trait anxiety (p = .042), and maladaptive coping (p = .002) over 12
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months. A subgroup of 74 participants, 34 in the +CBT group and 40 in the SC group,
classified as ‘in need’ was separately analyzed. Participants ‘in need’ were defined as
meeting at least one of the following criteria: aged 18-20, high baseline IBD activity
despite considered in IBD remission by the clinician (CDAI > 180; baseline SCCAI > 5),
being recently diagnosed (within last 2 years), having poor coping (score of 20-25 on
either adaptive or maladaptive coping), and high anxiety or depression (HADS score for
either anxiety or depression subscale > 15). Results from this subgroup showed that those
who received CBT had significantly improved mental quality of life at 6 months
compared to SC (p = .034, d = .56).21 At 12 months, the difference between groups
disappeared, but this subgroup as a whole decreased from 74 (+CBT n = 34 and SC n =
40) to 43 (+CBT n = 11 and SC n = 32). Although the results of this study did not
demonstrate that CBT significantly changed disease activity at 12 months, it showed that
participants ‘in need,’ such as those with a recent diagnosis or high anxiety or depression,
benefitted from CBT in improving mental quality of life. A possible explanation for why
this subgroup analysis failed to show improvement in anxiety or depression is the small
sample size.
This study had limitations that could potentially explain why CBT as an
intervention for all participants did not significantly change anxiety and depression scores
at 6 months when controlling for baseline. First, participants had low anxiety and
depression scores at baseline [+ CBT 4.3 (SD 3.4) and SC 4.4 (SD 4.1)], which could
explain how the intervention had little effect. The subgroup of participants ‘in need’ with
higher scores on mental health subscales showed that CBT was effective in improving
QoL at 6 months. Therefore, studies should focus on targeting psychotherapeutic
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interventions at those ‘in need’ vs the unselected IBD population. A second limitation
was high attrition. The attrition in the oCBT group was significantly higher than in the
F2F group. The sample size of the F2F group was 22 at baseline, 16 at 6 months, and 15
at 12 months, while the sample size of the oCBT group was 68 at baseline, 35 at 6
months, and 27 at 12 months. At 12 months, the significant difference between +CBT
and SC disappeared which can be attributed to this high attrition. Therefore, the analysis
became underpowered demonstrating the need for future studies to address high attrition
with possibly larger sample sizes. Lastly, offering the intervention group either F2F or
oCBT means this study did not classify as an RCT design. Additionally, there is no
certainty that the online self-help CBT usage accurately represents complete CBT usage.
Future studies should randomly allocate participants to a mode of CBT delivery or
choose only one mode with improved monitoring.
Another study was a parallel-group multicenter randomized controlled trial
investigating the effect of IBD-specific CBT on QoL, anxiety, and depression in IBD
patients with poor mental QoL.30 IBD patients with a low level of QoL (scores < 23 on
the SF-36) were randomized to an experimental group receiving CBT vs. a wait-list
control group receiving standard medical care for 3.5 months, followed by CBT. The
IBD-specific CBT intervention was eight 1-hour weekly sessions performed by eighteen
clinical psychologists specializing in CBT after 16 hours of training and regular group
supervision. Standard medical care involved consultation with medical specialists every 3
months for patients receiving immune suppression and once a year for patients not
receiving immune suppression. 118 adults (> age 18) diagnosed with either CD or UC
were eligible and randomized in the study. The average disease duration was 11.9 years
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in the experimental group and 10.4 years in the wait-list control group. Investigators
administered self-report questionnaires to measure the outcomes: IBDQ to measure
disease-specific quality of life, HADS—Depression Subscale (HADS-D) and Center for
Epidemiologic Studies Depression Scale (CES-D) to measure depression, HADS—
Anxiety Subscale to measure anxiety, and SF-36 to measure generic QoL. Both groups
completed these assessments at baseline and 3.5 months follow-up. Analyses of
covariance were used to assess difference between follow-up scores of all continuous
outcomes for both groups. Multiple imputation using chained equations (MICE) was used
as a sensitivity analyses to handle missing values. Data was then reanalyzed combining
results from 10 imputed data sets into pooled estimates.30 Mean scores on the continuous
outcomes were standardized to Cohen’s d using the pooled standard deviation of the
baseline scores for both completers group and the MICE group. Cohen’s d of .3, .5, and
.8, indicating a small, moderate, and large effect size, respectively, were calculated.30
CBT had a statistically significant decrease, with moderate effect size, in HADS
total score (d = 0.57, 95% CI -0.88 to -0.01), anxiety (d = 0.47, 95% CI -0.77 to -0.17),
and depression (d = 0.58, 95% CI -0.86 to 0.30) subscales at the 3.5-month follow-up. 30
CBT also showed significant effect on disease-specific quality of life (d = 0.55, 95% CI
0.27 to 0.84).30 When analyses was restricted to patients who attended at least five CBT
sessions, the per protocol results were similar to the intention-to-treat results. These
results demonstrated that CBT was effective in improving anxiety and depressive
symptoms, as well as disease-specific quality of life compared to the wait-list control
group.
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One strength of this study was the focus on a subgroup of IBD patients with lower
mental quality of life at baseline who would be at higher risk for psychiatric disorder and
who would benefit more from mental care. Another strength was the use of eighteen
clinical psychologists specializing in CBT who performed the intervention after a 16hour training and group supervision. This helps prevent significant changes in CBT
delivery among psychologists. There were also limitations of this study. The study was
somewhat underpowered for the primary outcome (n = 96 instead of the planned n =
128). However, statistically significant results for most outcomes were still observed and
the MICE calculations showed effect sizes similar to those in the complete case analysis.
Secondly, a wait-list control group is not optimal due to information bias of participants
knowing they will receive the intervention which may motivate participants to remain
depressed until they receive treatment.47 This may lead to exaggerated effect sizes
compared to a no treatment control group. There is a need to reconsider the attrition rate
assumption in order to calculate a sample size that will be adequately powered and
implement a control group that will provide the most accurate results of the intervention.
While no RCTs have directly studied the effect of CBT on IBD adults with higher
anxiety and/or depression at baseline, there is one randomized controlled trial studying
the effect of CBT on clinical disease course in adolescents and young adults with IBD
and subclinical anxiety and/or depression.29 Participants who scored above the cutoff of
the anxiety and/or depression questionnaire indicating elevated symptoms but not
meeting criteria for a psychiatric disorder were eligible for randomization. Participants
were randomized to either disease-specific CBT in addition to standard medical care or
standard medical care alone. Results found there was no significant difference of time to
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first relapse between the groups (p = 0.915).29 Additionally, clinical disease activity, fecal
calprotectin, and CRP did not significantly change over time between or within both
groups (p = 0.59, p = 0.158, p = 0.545, respectively).29 Strengths of this study include
focus on the IBD patients with elevated anxiety/depression symptoms, using standard
medical care as a control condition, low attrition, and use of objective measures for
clinical disease activity (fecal calprotectin and CPR). Limitations of this study are that
anxiety and depression symptoms were not investigated as an outcome, the majority of
participants were in clinical remission at baseline, and the majority of patients were of
Western ethnicity (80.9%), which reduces generalizability of the findings. Based on these
limitations, there still remains a need for the active disease population with elevated
anxiety/depression symptoms to be studied.
Lastly, a benchmarking study explored whether the benefits of CBT for IBD
adults with moderate to severe levels of anxiety or low mood will be superior in reducing
levels of anxiety and depression and having greater effect sizes in comparison with past
RCTs.48 Adults aged 18 and over with IBD who indicated moderate to severe levels of
anxiety and/or low mood, as scored by > 10 on the PHQ-9 or the Generalized Anxiety
Disorder 7 (GAD-7), were eligible for the nonrandomized uncontrolled trial. Participants
underwent weekly 50-minute therapy sessions. The therapist administering CBT was
trained in CBT and supervised by a cognitive behavioral psychotherapist familiar with
IBD. Primary outcomes were anxiety, as measured by GAD-7, and depression, as
measured by PHQ-9. Additional outcomes studied were HRQOL, using the short IBD
questionnaire (SIBDQ), and symptomatic disease activity, using the Harvey Bradshaw
Index (HBI) for those with CD and the simple clinical colitis activity index (SCCAI) for
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those with UC. Paired t-test was used to analyze pre- and post-measures of HRQOL and
disease activity. The two sample Wilcoxon rank sum test was used for analysis due to the
Shapiro-Wilks test for normality indicating that data may be skewed for post-measures of
anxiety (W = 0.053, df = 27, p = 0.01) and low mood (W = 0.758, df = 27, p = 0.001).
Additionally, in order to create a benchmark, an RCT with a 1:1 CBT intervention that
reported pre and post mean scores and standard deviations for measures of either anxiety,
low mood, quality of life, or disease activity, was needed to compare effects. Studies that
failed to report outcomes in this format or that used a group intervention were excluded.
The only study that remained consisted of two interventions (F2F CBT and online CBT)
vs. standard care,21 but for the purpose of composing a benchmark for this study, only the
outcome data from the online CBT group was used. Because this study used different
measures for their outcomes, it was not possible to directly compare the differences, so
uncontrolled effect sizes were calculated to standardize the treatment effects: 0.2 (small),
0.5 (medium), and 0.8 (large) using a time interval of 6 months.48
Results demonstrated a statistically significant decrease in scores for low mood (p
< 0.0001) and anxiety (p. < 0.001), symptomatic disease activity (CD: p = 0.002, UC: p <
0.001) and significant increases in scores for quality of life (p < 0.001). In the benchmark
comparison, large effect sizes in this study (depression: 1.9, anxiety: 2.0, quality of life: 2.09, disease activity: CD: 0.71, UC: 1.1) were seen compared to small-medium effect
sizes in the RCT21 (depression: 0.22, anxiety: 0.21, quality of life: not reported, disease
activity: CD: 0.06, UC: 0.13).48
This study demonstrates the benefits of CBT for IBD patients with moderatesevere depression and anxiety symptoms at baseline. These findings suggest the need for
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future RCTs to recruit participants of this subgroup. One limitation of this study was the
use of different depression and anxiety measurements in the between study comparisons.
It is possible that GAD-7 and PHQ-9 may be more sensitive to change in the IBD
population than HADS, used in the comparison RCT. Studies are lacking in which
questionnaires are best suited to measure anxiety and depression in IBD. However, the
biggest limitations were the small sample size, the design (uncontrolled, nonrandomized),
and therefore, lack of control group. Patients received a variable number of sessions
compared to the RCT, which may have confounded results. There is a need for a future
RCT investigating IBD subgroups in need vs. a control group that will control for
confounding variables and enhance generalizability.
2.3 Review of Relevant Methodology
2.3.1 Study Design
The proposed study will be a two-arm, single-blinded RCT investigating the
benefits of video-based CBT plus standard medical care compared to standard medical
care alone for 12 weeks on depression and anxiety in newly diagnosed IBD adults with
moderate-severe disease and moderate-severe depression and anxiety at baseline. The
study will recruit from the outpatient Yale Inflammatory Bowel Disease Center locations
at Temple Medical Center in New Haven, CT and in North Haven, CT. The study will be
conducted in the outpatient clinics and via video-based telemedicine using Zoom.
An RCT design was chosen due to previously conducted studies utilizing the RCT
design to compare CBT to a control group with a primary outcome of depression and
anxiety in adults with IBD. One study was described as a 2-arm parallel randomized
controlled trial, but their trial design offered the experimental group the choice of
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completing the CBT intervention face-to-face or online, which does not comply with
classic RCT requirements.21 Other studies used a wait-list control group vs. a standard of
care control group,26,30 which as discussed before, is not the ideal control condition.
Although it is an ethical alternative to provide treatment to a group in need of treatment,
it can alter participants behavior in knowing they will eventually receive the intervention,
which can affect study results. However, all participants will receive standard medical
care, which includes possible psychiatric referrals and treatment. The only study that
directly explored the benefits of CBT in IBD patients with moderate-severe depression
and anxiety symptoms was a nonrandomized, uncontrolled trial, limiting validity of the
results due to possible bias and confounders.48 Another study performed a subgroup
analysis of participants ‘in need’ (higher scores on mental health subscales), but the
sample size calculation was underpowered for this analysis.21 The other studies were
relatively underpowered due to small sample sizes26,48 or high attrition,29 which limits
generalizability. A parallel RCT study design to compare CBT vs. standard of care in
those with moderate-severe IBD and moderate-severe depression and anxiety symptoms
will reduce selection bias and minimizes possible confounders.
Participants will be recruited from clinics at the Yale University Inflammatory
Bowel Disease Program, a tertiary care center. Many of these patients may present with
moderate-severe disease courses, which is the subgroup of patients that the proposed
study is targeting.
2.3.2 Selection Criteria
A complete list of the inclusion and exclusion criteria can be found in Chapter 3.
Our selection criteria will be based on Bennebroek Evertsz et al., 2017.30 Participants will
35

be considered for our study if they are aged 18-40, have been diagnosed with either
Crohn’s disease or ulcerative colitis in the past 6 months, have been clinically diagnosed
with moderate to severe level of disease by a gastroenterologist, and have moderate to
severe levels of depression and/or anxiety at baseline assessments. Unlike previous CBT
studies who only included IBD adults with current clinical remission or mild symptoms
only21 or excluded those with elevated inflammatory markers, active disease24-26, or
severe disease (i.e., recent major surgery and/or complicated disease)23, we will enroll
those who score > 7 on Simple Endoscopic Crohn’s Disease (SES-CD) score for those
with CD49 or > 6 on Mayo Full Score or Mayo Endoscopic Score > 2 for those with UC.50
These are the cut-off scores between in remission/mild and moderate-severe disease.49
Many endoscopic disease scoring systems exist in IBD; one review investigated the most
common used scores in clinical trials of CD and UC. The two validated endoscopic
activity scores for CD are the SES-CD and Crohn’s disease endoscopic index of severity
(CDEIS).49 While CDEIS is the most commonly used endoscopic tool to assess disease
activity in clinical trials, it is limited by its complexity which requires training and
experience to utilize. Therefore, the SES-CD is a simplified index proven to be reliable,
and it correlates well with the CDEIS (correlation coefficient r2 = 0.920).49 The most
commonly used endoscopic tool to assess disease activity in UC is the Mayo endoscopy
sub-score. Strengths of this include ease of use and frequency of use in clinical trials, but
limitations include lack of validation. One study defined active UC with a Mayo score of
6-12 points or endoscopic sub-score of at least 2.50 These cut-off scores have been used in
other clinical trials.51 See Table 1 for disease activity indices scoring ranges and
Appendices G and H for complete layout of scores.
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Table 1. Inflammatory Bowel Disease Activity Indices

Inactive Disease
Mild Disease
Moderate
Disease
Severe Disease

SES-CD (Score
Range: 0-56)
<2
3-6

UC Mayo Score (Score
Range: 0-12)
< 2 and no subscore > 1
3-5

UC Mayo Endoscopic
Subscore (Score Range: 0-3)
0
1

7-15

6-10

2

> 16

11-12

3

Baseline assessments will be administered upon enrollment into the study.
Participants with other severe psychiatric disorders, already undergoing treatment for
mental health problems (pharmacological and/or psychological), significantly cognitively
impaired, undergoing other interventional studies, or having feelings of suicidal ideations
will be excluded from our study. This exclusion criteria helps to prevent several factors
from potentially interfering with the validity of the results.
2.3.3 Potential Confounding Variables
There are potential confounding variables that can threaten the validity of our
proposed study. Similar to previous studies, these variables include gender, age,
employment status (full-time or part-time), level of education, diagnosis (UC or CD),
disease duration, medications (steroids or biologics), current stoma, or other chronic
illnesses.21,25,30 Another confounding variable will be changes in medication, such as the
initiation of antidepressant as standard care by a psychiatrist during the study. We will
control for these variables with a randomization protocol and account for differences
between groups.
2.3.4 Randomization and Blinding Technique
Randomization techniques will be similar to previous studies investigating the
effectiveness of CBT on anxiety and depressive symptoms among patients with IBD.29,30
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After baseline assessments are completed, eligible participants will be randomized using
a computer-generated program into a 1:1 allocation to the intervention and control
groups. This controls for baseline characteristics and reduces potential bias from
confounding variables between and among both groups.
It is not possible to blind the experimental group to their intervention, but the
control group can be blinded to the study’s hypothesis and specific details of the
intervention. In accordance with another study, the investigators obtaining assessments
and providers assessing disease activity will be blinded; participants in the intervention
group will be asked not to discuss their outcome of randomization with their treating
providers.29
2.3.5 Intervention
The video-based CBT intervention will be based on the framework of previous
studies utilizing traditional CBT22 and video-based CBT in other populations.40 This
intervention will model that of traditional face-to-face CBT but delivered by a therapist
online via video-based platform. Our CBT program content will follow the 10-week
program utilized in the 2017 study by Mikocka-Walus et. al; it focuses on improving
coping with IBD.22 Two previous studies added booster sessions following their 10-week
CBT program.29,52 These sessions give patients the opportunity to reinforce progress or
trouble shoot obstacles, which may improve long-term outcomes.23 A systematic review
found that CBT with booster sessions are more effective for mood and anxiety orders
than CBT interventions without a booster session.53 Similar to another study that
investigated therapist-delivered internet psychotherapy for depression in primary care,
every participant will be assigned to one therapist for the duration of the study.40 Length
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of CBT sessions have varied in previous studies from 55 minutes to 2 hours.20,22,40
Another study considered participants as treatment completers if they attended a
minimum of 8 sessions.29 The proposed study will be a combination of these studies: a
12-week CBT program consisting of the 10-week content with 2 additional booster
sessions. Sessions will be one hour in length and participants need to complete greater
than 8 sessions to be considered intervention completers.
Trained psychologists specialized in CBT will conduct the sessions. These
psychologists must be experienced in working with and treating depression and anxiety
disorders. Following the methodology of one RCT,30 CBT sessions will be recorded, and
independent raters will conduct integrity checks on at least two treatments per therapist.
The control group will remain standard medical care. Because the patient
population will be those with newly diagnosed IBD, all patients will have undergone a
colonoscopy and/or endoscopy to establish their baseline disease severity. Standard
medical care typically includes follow-up visits with gastroenterologists that can include
lab draws, initiation of pharmacologic, steroid, or biologic treatment, or procedures.
Standard medical care will also extend to psychiatric referrals made by
gastroenterologists and therefore, pharmacologic treatment initiated by psychiatrists.
2.3.6 Primary and Secondary Outcomes
The primary outcome of this study is depression and/or anxiety as measured by
the Hospital Anxiety and Depression Scale (HADS). HADS has been widely studied in
the past as a reliable screening measure for depression and anxiety disorders.54 Patients
with IBD can experience both depression and anxiety, so the HADS scale was chosen as
the primary outcome measurement. While the Patient Health Questionnaire (PHQ-9)25
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and the Beck Depression Inventory (BDI)29,52 has been used in past studies to assess
depression in patients with inflammatory bowel disease, it is limiting because it does not
include anxiety symptoms. However, PHQ-9 does have the advantage of asking about
thoughts of death.55 Because of this, we will have to include questions asking about
suicidal ideations and/or plans prior to screening. The HADS scale is divided into two
scores, HADS-A for anxiety and HADS-D for depression.
In a 2002 systematic literature review, researchers found that using a cut-off score
of 8 for both HADS-A and HADS-D provided the most optimal sensitivities and
specificities around 0.80.56 In this review, three studies in primary care populations
investigated HADS as a tool to detect DSM-III-defined psychiatric morbidity. Using 8+
as a threshold, the AUCs were analyzed to find the optimal threshold and all three studies
showed 0.84-0.96, demonstrating that a score of 8+ on the HADS was reliable in
identifying depression and/or anxiety.56
A 2018 study looked into the validity and reliability of screening measures for
depression and anxiety disorders in people with IBD. This study had people with IBD
complete a Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID), in
addition to multiple depression and anxiety screenings: PHQ-9, HADS, Kessler-6
Distress Scale, PROMIS Emotional Distress Depression Short-Form 8a (PROMIS
Depression) and Anxiety Short-Form 8a (PROMIS Anxiety), GAD 7-item Scale, and
Overall Anxiety and Severity Impairment Scale. For the HADS subscales, this study used
a published cut-off point of 8 for possible anxiety and depression and 11 for probable
anxiety or depression.55 HADS-D had an internal consistency reliability of 0.84 (95% CI,
0.76-0.92) and test-retest reliability of 0.83 (95% CI, 0.77-0.87). HADS-A had an
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internal consistency reliability of 0.87 (95% CI, 0.79-0.95) and test-retest reliability of
0.83 (95% CI, 0.77-0.87). Researchers found that there were not significant differences in
the individual psychometric properties of the different symptom scales. There are
advantages and disadvantages to each scale, and there needs to be a balance of both
sensitivity and specificity. The advantage of HADS is that it simultaneously evaluates
depression and anxiety, two disorders that often co-occur, and is designed specifically for
use in medically ill populations. Because of this, we will use HADS to measure our
primary outcome. See Appendix E for HADS scoring.
One secondary outcome will be quality of life, as measured by the Short Form-12.
This is a self-report questionnaire that is a simplified version of the SF-36. It is a generic
quality of life survey that is broken down into two subscales: physical and mental health.4
Higher scores correspond with better quality of life.57 An advantage of the SF-12 over the
IBDQ, another widely used disease-specific questionnaire that measures HRQOL in
patients with IBD, is that it consists of 12 items that assess eight health concepts: (1)
physical functioning, (2) role-physical, (3) bodily pain, (4) general health, (5) vitality, (6)
social functioning, (7) role-emotional, and (8) mental health, whereas, the IBDQ consists
of 32-items that only explore four dimensions: (1) bowel symptoms, (2) systemic
symptoms, (3) emotional function, and (4) social function.57 Another advantage of SF-12
is that scores are norm-based and have been standardized from a national probability
sample of 6012 noninstitutionalized adults in the US who participated in a 2009 Internetbased survey.58 See Appendix F for SF-12 scoring.
Other secondary outcomes include objective measures of disease activity,
measured by systemic inflammatory markers: complete blood count (CBC), erythrocyte
41

sedimentation rate (ESR), C-reactive protein (CRP), and a local inflammatory maker:
fecal calprotectin (FCP). As stated before, the severity of IBD inflammation and its
associated symptoms can lead to depression/anxiety, while depression/anxiety can
exacerbate inflammation.59 Furthermore, this bi-directional relationship implies an
improvement in depression/anxiety symptoms will be accompanied by an improvement
in inflammation.29 Due to the other outcomes being measured by self-reporting, it is
important to gather objective data to ascertain whether improvements in disease activity
were caused by reduction in inflammation or changes to perception of symptoms.48 A
recent systematic review found that the measuring of both systemic and local
inflammatory markers has only been done in three past studies looking at nonpharmacological interventions for anxiety and depression in adults with IBD;32,34,35,37
none used CBT as their intervention.
2.3.7 Sample Size and Statistical Significance
We will calculate our sample size from a previous study that used CBT as an
intervention and the HADS to measure one of their outcomes.30 This study found a mean
difference of 1.04 in total HADS score for the control group and a mean difference of
6.30 in total HADS score for the intervention group. These differences were taken from
the total HADS score at baseline and at 3.5-month follow-up in intention to treat analysis.
We calculated the standard deviation for difference between means in both the control
group and the intervention group. The standard deviation for the control group was 1.46,
while the standard deviation for the intervention group was 1.38. We will maintain a
power of 80%, alpha of 0.050, and two tails. Previous RCTs studying CBT in unselected
IBD have assumed a 10% attrition rate,25,30 but their results were still underpowered due
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to higher than anticipated dropouts. One study focusing on youth with IBD and
subclinical anxiety and/or depressive symptoms at baseline had very low attrition
(<3%).52 Because our proposed study will be selecting similar adult IBD patients, we
expect low attrition. However, we will still use an estimated 10% attrition rate, which
results in a sample size of 70 participants in each group, or 140 total participants needed
for recruitment into our study.
2.4 Conclusion
This literature review demonstrates the need to study CBT in newly diagnosed
adults with moderate-severe IBD and moderate-severe depression/anxiety at baseline of
diagnosis. Due to adherence challenges with traditional CBT, this review demonstrates
evidence supporting the use of a video-based, therapist-guided online CBT in the IBD
population. Research has shown CBT as an effective treatment for depression and anxiety
symptoms in IBD. However, no studies currently exist using video-based CBT as an
intervention. Past studies have largely remained underpowered due to high attrition rates.
Additionally, past studies have failed to focus on the subgroup in most need of a
psychotherapeutic intervention: those with moderate to severe IBD. Our proposed study
is a single-blinded RCT studying the effects of video-based CBT compared to standard
care in newly diagnosed IBD patients with moderate-severe disease and moderate-severe
depression/anxiety at baseline. This addition to the literature will inform providers on
additional treatment that can be initiated upon new diagnoses of IBD.
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CHAPTER 3: METHODS
3.1 Study Design
The study design will be a two-arm, single-blinded RCT. The study will comprise
of randomization to a 12-week intervention or standard care with a 6-month follow-up
from start of intervention of both groups. The research staff will create a Qualtrics survey
to measure the primary outcome (change in depression/anxiety measured by HADS) and
the secondary outcome (change in quality of life measured by SF-12). Participants will
fill out forms at the start of the study, weekly for 12 weeks, and 3 months after
completion of intervention. This survey will be sent via email along with weekly
reminder emails to complete these questionnaires. Participants will undergo lab testing at
either Yale New Haven Hospital or any Quest lab in the surrounding area.
3.2 Study Population and Sampling
Participants will be sampled on a non-random, consecutive basis from the
outpatient Yale Inflammatory Bowel Disease Program at Temple Medical Center in New
Haven, CT and North Haven, CT. Participants will have a primary diagnosis of IBD
confirmed endoscopically by gastroenterologists at these locations. See Table 1 for a
complete list of inclusion and exclusion criteria. At baseline, each participant will receive
an endoscopic score, Ulcerative Colitis Mayo Score for those with UC and Simple
Endoscopic Score for Crohn’s Disease (SES-CD) for those with CD. Only those scoring
> 7 on the SES-CD score for those with CD or > 6 on the Mayo Full Score or > 2 on the
Mayo Endoscopic Score for those with UC will be included in the study. Patients with
appointments at these locations will complete the Hospital Anxiety and Depression Scale
(HADS). Those scoring > 8 in depression and/or anxiety on the HADS and diagnosed
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with moderate to severe IBD in the past 6 months will be asked to participate in the
study. Because HADS does not include suicidal questions, participants will be asked if
they have thoughts or plans to commit suicide or harm themselves; these participants will
be immediately referred to a psychiatrist and excluded from the study.
Participants will also complete the Short Form-12 (SF-12) that measures HRQOL.
Inflammatory markers: complete blood count (CBC), erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), and fecal calprotectin will be measured. Other labs that
will be measured at baseline are a comprehensive metabolic panel (liver and renal levels),
thyroid-stimulating hormone (TSH), vitamin B12, folate, and iron. Additional baseline
variables that will be obtained are stools per day, blood in stool, pain, fever, joint pain,
appetite, weight loss or gain, all medications, and pathology results from colonoscopy.
Baseline characteristics will be measured following enrollment into the study.
Table 2. Inclusion and Exclusion Criteria
Inclusion Criteria
•
•
•
•

•
•
•
•

Exclusion Criteria
•

Age 18-40
Recent clinical diagnosis (< 6
months) of IBD (either UC or CD)
Sufficient English to understand,
answer questionnaires, and
participate in therapy
Access to
computer/Internet/smartphone
device that is sufficient for video
conferencing/telemedicine
Competence to consent
Willingness to participate in CBT
sessions
Baseline score of > 7 in depression
and/or anxiety on the HADS
Baseline score of > 7 on the SESCD score for those with CD or > 6

•

•
•
•

50

Diagnosis of selective mutism,
bipolar disorder,
schizophrenia/psychotic
disorder, autism spectrum
disorders, post traumatic or
acute-stress disorder, or
substance use disorder
Current or past treatment for
mental health problems
(pharmacological and/or
psychological)
Significant cognitive impairment
Participation in another
interventional study
Participants with severe levels of
depression (i.e., associated with
suicidal ideations)

on the UC Mayo Score or > 2 on the
Mayo Endoscopic Score for those
with UC

3.3 Subject Protection and Confidentiality
IRB approval will be obtained following the Yale University IRB Policy 100. All
staff interacting with research participants will be required to complete the Yale Human
Subject Protection and HIPAA Privacy training prior to the start of the study. Only those
who have completed this training can access private health information (PHI) in
university-approved secure electronic health records (EHR) on encrypted devices.
Encryption of home video devices will align with Yale IRB protocol. Eligible subjects
will be required to complete a written, informed consent form that follows Yale’s IRB
Policy 200 for Informed Consent for Human Research. This consent form will detail the
study’s purpose, procedures, duration, benefits, and statements of confidentiality. Data
will be de-identified to ensure confidentiality. The form will also state that participants
may discontinue the study at any time, and researchers may remove participants from the
study at any time (i.e., if participants indicate suicidal thoughts after being randomized).
All participants will be given time to read and ask questions regarding the IRB approved
consent forms, attached in Appendices A and B.
3.4 Recruitment
The primary recruitment process will involve informing providers at the Yale IBD
Program at Temple Medical Center in New Haven and in North Haven of the study. A
list will be generated of eligible subjects (newly diagnosed, moderate-severe IBD).
Providers will assist in identifying eligible subjects who were not contacted. Providers at
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these clinics will introduce the study to eligible subjects, and research staff will provide
detailed information about the risks and benefits for those interested. Research staff will
schedule appointments in the clinics for informed consent and to conduct baseline
assessments. Subjects will be recruited with ongoing enrollment for 1.5 years.
3.5 Study Variables and Measures
Video-Based Cognitive Behavioral Therapy Intervention: The video-based,
therapist-guided CBT intervention will consist of twelve, 60-minute individual sessions
for 12 weeks. The intervention will model face-to-face traditional CBT but will be
administered via video conferencing. There will be 2 qualified CBT psychologists trained
in treating depression and anxiety and supervised at a specific location. We will base the
weekly sessions on the content from the Mikocka-Walus study1 (see Appendix C) with
the addition of 2 booster sessions. The booster sessions will give participants the
opportunity to re-visit activities, techniques, or lessons learned in the first 10 weeks.
Participants will have weekly appointments scheduled in their Epic MyChart for 12
weeks. They will connect to a therapist via Zoom for their weekly sessions. At any point
during the study, if patients’ depression and/or anxiety symptoms significantly worsen
(i.e., suicidal thoughts or plans), they will be offered immediate evaluation/management
by a psychiatrist.
Control Group: Patients will receive standard medical care. This includes
pharmaceutical or surgical interventions by their gastroenterology providers along with
the usual follow-up visits. This also includes psychiatry referrals as deemed necessary by
the gastroenterologists. Furthermore, if a psychiatrist initiates pharmacologic medication,
such as an antidepressant, this will constitute as standard medical care. As with the
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intervention group, if symptoms worsen (i.e., suicidal thoughts) of patients in the control
group, they will be offered further evaluation/management by a psychiatrist.
Primary and Secondary Outcomes: The primary outcome for this study is
significant improvement in depression and anxiety, as measured by the Hospital and
Anxiety Depression Scale (HADS), with 12 weeks of CBT intervention. Secondary
outcomes include significant improvement in quality of life, as measured by the Short
Form (SF-12), in patients who receive CBT compared to standard care alone.
Baseline Variables: Participants will be asked to complete a survey at baseline to
ask their age, gender, income, stools per day, blood in stool, pain, fever, joint pain,
appetite, weight loss or gain, biologic use, steroid use (i.e., prednisone), any medications,
any surgeries, diagnosis of ulcerative colitis vs Crohn’s disease, and other co-morbid
diseases. Additional laboratory tests that will be drawn at baseline are a comprehensive
metabolic panel, which includes liver and renal tests, thyroid-stimulating hormone
(TSH), vitamin B12, folate, and iron. Participants will undergo colonoscopies at baseline
and receive a SES-CD or Mayo score at that time. The pathology results from these
procedures will also be recorded at baseline. Participants will complete the HADS and
SF-12 at baseline, in addition to, completing the blood tests (CBC, ESR, CRP) and stool
test (fecal calprotectin) at baseline. See Appendix D for schedule of assessments.
3.6 Methodology Considerations
Blinding of Intervention: Due to the nature of this intervention, it cannot be
blinded to participants in the experimental group. Therapists administering CBT cannot
be blinded, and therefore, will not participate in data collection or outcome assessments.
However, we will blind the control group from the study’s hypothesis and content of the
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intervention. Participants in the intervention group will be asked not to discuss their
outcome of randomization with their treating gastroenterology providers, other study
participants, and members of the research staff performing outcome assessments.
Blinding of Outcome: Subjects are unable to be blinded to the outcome due to
their participation in completing questionnaires at baseline, throughout 12 weeks, at 12week completion, and 3-month follow-up. However, investigators and outcome accessors
will be blinded to the allocations throughout the study.
Adherence: Adherence to the intervention will be ensured by subjects’
participation in sessions with CBT therapists. There will be an independent evaluation of
intervention session recordings to ensure protocol and treatment consistency. Consent for
these sessions recordings is detailed in Appendix B.
3.7 Assignment of Intervention
Following completion of baseline assessments, we will verify subjects’
motivation to undergo the CBT intervention prior to randomization. Subjects will be
randomly allocated at a 1:1 ratio using a computerized random number generator. One
member of the research team will perform the randomization and allocation concealment.
This individual will not be involved in the rest of the study. Investigators and other
research staff performing outcome assessments will be blinded to this allocation.
3.8 Data Collection
Data will be collected over 12 weeks and there will be a 6-month follow-up from
start of intervention. Questionnaires will be administered online following each weekly
session. Patients will have laboratory tests drawn and submit a stool test to measure
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levels of inflammatory markers at baseline, 12 weeks, and 3 months after completion of
the study. Patients will undergo a colonoscopy at completion of the study.
3.9 Sample Size Calculation
This study will utilize a two-sided hypothesis with a statistical significance of
alpha of 0.05 and power of 80%. A simple t-test calculator G*Power version 3.1.9.6 was
used to look for a difference in means on the HADS. Using a previous study, we first
calculated the standard error of the mean (SEM) of the intervention and control groups at
both baseline and 3.5-month follow-up. We then calculated the standard deviations for
the difference between two sample means. A sample size of 128 participants, with 64
participants in each group, was calculated (Appendix I). Based on prior studies, the
sample size will account for an estimated 10% dropout rate. Therefore, the adjusted
sample size will be 140 participants, with 70 participants in each group.
3.10 Analysis
Baseline characteristics will be analyzed to describe the study sample and to
identify statistically significant differences between randomized groups that could be
potential confounders in this study. Age and stools per day are continuous variables that
will be reported as means with standard deviations. Student t-tests will be used to
compare continuous variables at baseline. Income, blood in stool, pain, fever, joint pain,
appetite, weight loss or gain, biologic use, steroid use, other medications, surgeries,
family history of IBD, diagnosis of UC vs. CD, pathology from the colonoscopy, and
other co-morbid diseases are categorical variables that will be reported as frequencies.
Chi-square tests will be used to compare categorical variables at baseline.
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Intention-to-treat analysis will be used for primary and secondary outcome data.
Baseline scores on the HADS and SF-12 will be compared between groups using a
student t-test. Baseline levels from the CBC, ESR, CRP, and fecal calprotectin will also
be compared between groups using a student t-test. The primary outcome, mean change
in HADS score, will be operationalized as a continuous variable. Paired sample t-tests
will be run to examine changes within groups over time. Mixed design analyses of
covariance will be run to assess differences between follow-up scores for all continuous
outcomes for the groups while controlling for baseline variables. Multivariate regression
will be run for multivariate analysis, compensating for any missing data.
3.11 Timeline and Resources
The proposed study will take place within two years, from gathering participants
to data collection. See Figure 1 for the study’s timeline. Recruitment of participants will
take place over the first 1.5 years. The intervention will be 3 months. Follow-up
assessments will take place at the end of intervention and at 3 months after completion of
the intervention. Data analysis will be completed within 6 months of study completion.
The principal investigator (PI) will be Deborah Proctor, MD, and the co-principal
investigator (co-PI) will be Monica Narsolis, PA-SII. Colonoscopies establishing
diagnoses will occur at Yale New Haven Hospital. All participants will receive standard
medical care at the Yale IBD Center locations at Temple Medical Center in New Haven,
CT and in North Haven, CT or at outpatient Yale psychiatric clinics in New Haven, CT.
Providers at these clinics will be informed about the proposed study and administer
baseline questionnaires (HADS and SF-12) to those documented with newly diagnosed,
moderate-severe IBD. Research assistants at Yale University will collect baseline
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questionnaires and determine eligible patients for our study. CBT psychologists/therapists
will be recruited from the region and compensated for their time.
Figure 1. Timeline of Intervention
18 months
3.12
References
Ongoing
recruitment
and enrollment

3 months
Intervention period
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3 months
Follow-up
assessments
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Medicine. 2017;24(1):127-135.
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CHAPTER 4: CONCLUSION
4.1 Advantages and Disadvantages
This study will be the first RCT comparing video-based CBT to standard medical
care in improving depression and anxiety symptoms in newly diagnosed IBD adults with
moderate-severe disease and moderate-severe depression and/or anxiety symptoms at
baseline. Our proposed study will be novel because we will target those with moderate to
severe IBD, unlike previous studies,1-4 and those with greater psychological distress.5,6
Through an RCT design, we hope to gain insight into the effectiveness of CBT by
minimizing potential bias from confounding variables. Unlike past studies with high
attrition and low adherence to a CBT intervention, we hope to conduct an adequately
powered study by utilizing video-based CBT. This will likely increase overall adherence
due to its convenience, which will increase generalizability of our results. Finally, the
addition of objective measures of disease activity will reveal more insight into the
bidirectional relationship between depression/anxiety and IBD.
There are some limitations to our study design that we will consider. First, we
were unable to design our study into four categories: 1. mild/in remission IBD and mild
depression/anxiety, 2. mild/in remission IBD and moderate/severe depression/anxiety, 3.
moderate/severe IBD and mild depression/anxiety, and 4. moderate/severe IBD and
moderate/severe depression/anxiety. To create a study with a feasible sample size, we
chose to narrow our study to the last category based on previous research showing the 4th
group would likely benefit the most from CBT. However, due to our novel use of videobased CBT compared to standard care in the IBD population, being able to investigate its
effectiveness in all four groups could provide more insight into implementing its use in
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standard of care. Second, we can only conduct a single-blinded design which presents the
potential for participant bias towards their intervention placement. We hope to mitigate
adverse effects on results by blinding all participants to the hypothesis of our study.
Lastly, participants are required to complete questionnaires weekly for 12 weeks and at 3month follow-up. To minimize respondent burden and questionnaire fatigue, we chose 2
relatively short, validated measures, HADS and SF-12. This will improve the potential
for missing data and information bias that could affect the study’s outcomes.
4.3 Clinical and Public Health Significance
Inflammatory bowel disease is a chronic, relapsing-remitting disease requiring
life-long management with medications and invasive procedures, which has the potential
to negatively impact one’s quality of life. It is well-known that those with IBD are at
increased risk for depression/anxiety, but there is no standard treatment for those who
present with moderate to severe depressive and anxiety symptoms at initial IBD
diagnosis. It is important that providers recognize these symptoms and have evidencebased guidelines for management. While antidepressants are effective in managing these
symptoms, non-pharmacologic treatment should be considered as an additional option in
a population with a high medication burden. Preventing a secondary diagnosis of
depression and/or anxiety can future prevent hospitalizations and decrease healthcare
costs. Also, improving depressive and anxiety symptoms may inadvertently improve
disease flares. If the findings of this study improve depression and/or anxiety, providers
will have evidence that video-based CBT can be recommended for this group. Overall,
this study will highlight modern-day medicine’s transition into video visits while
enhancing this chronic disease’s management.
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APPENDICES
Appendix A: Participant Consent Form
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
YALE UNIVERSITY SCHOOL OF MEDICINE
YALE NEW HAVEN HOSPITAL
Study Title: Video Cognitive Behavioral Therapy to Prevent Depression in Patients with
Inflammatory Bowel Disease
Principal Investigator: Deborah Proctor, MD
Co-Investigator: Monica Narsolis, PA-SII
Funding Source: Pending
Invitation to Participate and Description of Project
You are invited to participate in a research study investigating depression and anxiety in
inflammatory bowel disease patients using either a video-based psychotherapy
intervention (cognitive behavioral therapy) or standard medical care. Standard medical
care includes appointments, surgeries, or treatments performed by your
gastroenterologists. If your gastroenterologist refers you to a psychiatrist for your
symptoms, standard medical care will include appointments or treatments deemed
appropriate by them. You have been asked to participate because you have been recently
diagnosed with inflammatory bowel disease and are an adult age 18-40. Approximately
140 people will participate in this study.
In order to decide whether or not you wish to be a part of this research study you should
know enough about its risks and benefits to make an informed decision. This consent
form gives you detailed information about the research study, which a member of the
research team will discuss with you. This discussion should go over all aspects of the
research: its purpose, the procedures that will be performed, any risks of the procedures,
possible benefits, and possible alternative treatments. Once you understand the study, you
will be asked if you wish to participate; if so, you will be asked to sign this form.
Description of Procedures
If you are interested in this study, you will be asked questions about your health to
determine if you are eligible for this study. Information will be collected about your age,
current depression and anxiety symptoms, history of depression and anxiety treatments,
and current severity of IBD. Before the study begins, you will have completed a
colonoscopy and/or endoscopy to diagnose your IBD. At your initial visit with your
gastroenterologist following this procedure, you will complete the Hospital Anxiety and
Depression Scale, a form used to assess levels of anxiety and depression. Depending on
your score, you will be asked to participate in this study.
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If you agree to participate in this study, you will be randomly assigned to one of two
groups. Both groups will receive standard medical care, but one group will undergo
cognitive behavioral therapy in addition to their care. Random assignment is like flipping
a coin with a 50/50 chance of one group or the other. Randomization will be done by a
computer program and will not be based on any personal baseline information. Your
providers will have no influence or knowledge of which group you are randomly
assigned to. Those in the cognitive behavioral therapy group will be asked to attend a
one-hour session once a week for 12 weeks. During these sessions, participants will
interact with a therapist one-on-one online using a videoconferencing platform.
Participants will be allowed to undergo these sessions at home or any location that is
most convenient for them. You will receive reminder calls or texts for sessions from a
research assistant.
Both groups will be asked to undergo laboratory testing and submit a stool sample at the
start of the study, 12 weeks following the start of the study, and 6 months following the
start of the study. These will be completed either at the lab at Yale New Haven Hospital
or any Quest lab in the surrounding New Haven, CT area. Parking will be free of charge.
During the course of the study, you will be asked to refrain from any self-help cognitive
behavioral therapy at home.
At the start of the study, you will complete 2 questionnaires regarding your depression,
anxiety, and quality of life. You will also complete these questionnaires weekly for 12
weeks, and at 6 months following the start of your study. We will create a Qualtrics
survey and send the link via text message or email to complete. You will receive
reminder calls or texts to complete the questionnaires from a research assistant.
Throughout the study, you will follow up with your gastroenterologists to receive care for
your inflammatory bowel disease. These appointments will take place at the Yale IBD
Center locations at Temple Medical Center in New Haven, CT and in North Haven, CT.
This will be identical to the routine care you would receive regardless of participating in
this research study. Your gastroenterologists will have no knowledge of which group you
are randomly assigned to. This is done so that a fair evaluation of the results can be made.
Medical Record Access:
If you decide to participate in this study, researchers will also access to your medical
records for information related to your IBD. They will examine your type of IBD
(Crohn’s disease or ulcerative colitis), the location of your disease, when you were
diagnosed, pathology results from the colonoscopy, laboratory results related to your IBD
(white blood cell count, comprehensive panel (liver and renal tests), thyroid-stimulating
hormone, vitamin B12, folate, iron, erythrocyte sedimentation rate, c-reactive protein,
and fecal calprotectin), and finally any other disease diagnoses you have. This
information will be used to determine whether these factors alter any of the other
measurements in the study.
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You will be told of any significant new findings that are developed during the course of
your participation in this study that may affect your willingness to continue to participate.
If research results are published, your name and other personal information will not be
given.
Risks and Inconveniences
We do not anticipate any major risks in participating in this study. For both groups, your
gastroenterologists will provide referrals to appropriate providers if needed to treat your
depression and anxiety symptoms. This may include initiation of antidepressant
medications, which has the potential risk of side effects. The prescribing providers will
discuss these in detail with you prior to starting any medication. For the group receiving
cognitive behavioral therapy, you may feel emotionally uncomfortable or more upset at
times because it can cause you to explore painful feelings, emotions, and experiences.
Your therapist will help you talk through your negative feelings.
Questionnaire contents may include personal information related to physical and
psychological symptoms, so there is a risk of breach of confidentiality about your health
status and participation in this study. However, this is unlikely to occur. All research staff
will be thoroughly trained and certified in the privacy of research studies.
Benefits
Benefits of participation in this study may include improvements in managing mental
illness, preventing relapse of mental illness symptoms, learning techniques to cope with
stressful situations, identifying ways to manage emotions, coping with your new
diagnosis of IBD, and managing chronic physical symptoms.
Economic Consideration
There is no direct compensation associated with this study. Cognitive behavioral therapy
will be delivered by therapists online using Zoom as the video-based platform. This
requires access to a computer, iPad, or smartphone device that is sufficient for video
conferencing. For those that do not own either of these devices, we will provide you with
an iPad for the duration of the study.
Parking will be reimbursed at each clinic or laboratory appointment. You will still be
responsible for any co-pays required by your insurance company for standard treatment.
If you have any questions regarding your insurance coverage, please contact your
insurance company directly. There will be no financial penalty for withdrawing for the
study.

Treatment Alternatives
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The alternative to participating in this study is to decline participation. If you do not wish
to participate you will be provided the standard treatment for your mental health at the
discretion of your healthcare provider.
Confidentiality and Privacy
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as permitted by U.S. or
state law. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases. Information will be kept
confidential by using only identification numbers on study forms, storing signed forms in
locked cabinets, and password protecting data stored on a computer. When the results of
the research are published or discussed in conferences, no information will be included
that would reveal your identity unless your specific permission for this activity is
obtained.
All subjects will be assigned a Yale Central Authorization Service (CAS) ID that ensures
secure sessions with therapists and online forms.
Information about your study participation will be entered under a unique identification
number in a password-protected software and stored on a secure Yale server until needed
for statistical analysis. Health Insurance Portability and Accountability Act (HIPAA)
standards will be met and maintained for all devices and personnel. Only approved
research personnel will have access to your medical records in order to verify information
required for the study. Any information that in not relevant will not be extracted from
your medical records. Data auditing will be performed at random points throughout the
trial to ensure no inappropriate viewing or disclosure of protected health information has
occurred All records no longer needed for research purposes will be shredded and
destroyed in accordance with HIPAA requirements. All data and records used in the
study will be kept for 10 years after data analysis has concluded.
Representatives from Yale University, the Yale Human Research Protection Program,
and the Yale Human Investigation Committee (the committee that reviews, approves, and
monitors research on human subjects) may inspect study records to ensure research
compliance. These individuals are required to keep all information confidential.
By signing this form, you authorize the use and /or disclosure of the information
described above for this research study. The purpose of the uses and disclosures you are
authorizing is to ensure that the information relating to this research is available to all
parties who may need it for research purposes.
Voluntary Participation and Withdrawal
Participating in this study is voluntary. You are free to choose not to take part in this
study. Refusing to participate will involve no penalty or loss of benefits to which you are
otherwise entitled (such as your health care outside the study, the payment for your health
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care, and your health care benefits). You will not be able to enroll in this study and will
not receive study procedures as a participant if you do not allow use of your information
as part of this study.
If you do become a subject, you are free to withdraw from this study at any time during
its course. To withdraw from the study, you can call a member of the research team at
any time and tell them that you no longer want to take part. Also, the researchers may
withdraw you from participating in the research if necessary. Withdrawing from the study
will involve no penalty or loss of benefits to which you are otherwise entitled. It will not
harm your relationship with your own providers or with Yale School of Medicine. When
you withdraw from the study, no new health information identifying you will be
gathered. Information that has already been gathered may still be used and given to others
until the end of the research study, as necessary to ensure the integrity of the study and/or
study oversight.
You do not give up any of your legal rights by signing this form.
Questions
We have used some technical terms in this form. Please feel free to ask about anything
you do not understand and to consider this research and the consent form carefully—as
long as you feel is necessary—before you make a decision.
Authorization and Permission:
I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purpose, the particulars of my involvement, and
possible hazards and inconveniences have been explained to my satisfaction. My
signature also indicates that I have received a copy of this consent form.
By signing this form, I give permission to the researchers to use [and give out]
information about me for the purpose described in this form. By refusing to give
permission, I understand that I will not be able to be in this research study.
Name of Subject: ______________________________________
Signature: ____________________________________________
Date: __________
_______________________________________
Signature of Principal Investigator

_______________
Date

Or
_______________________________________
Signature of Person Obtaining Consent
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________________
Date

If after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at (203) 432-5919.
If you have further questions about this project or if you have a research-related problem,
you may contact the co-Principal Investigator, Monica Narsolis. If you would like to talk
with someone other than the researchers to discuss problems, concerns, and questions you
may have concerning this research, or to discuss your rights as a research subject, you
may contact the Yale Human Investigation Committee at (203) 785-4688.
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Appendix B: Video/Audio Recordings Consent Form
Video Cognitive Behavioral Therapy to Prevent Depression in Patients with
Inflammatory Bowel Disease
Consent to Video/Audio Recordings
200 FR 6 (2014-1)
We are requesting your permission to record your video sessions as part of this study. If
you agree to the recording, we will use the video or audio recordings for independent
raters to conduct integrity checks and on at least two treatments per therapist. In addition,
we would like your permission to keep the recordings to ensure protocol is being
maintained and treatments are staying consistent. The recording is optional. You may
choose to give permission for one or both uses of the recordings, or you may decide not
to participate in taping at all. Your decision will not affect your ability to remain in the
study.
If you agree to participate, we will keep the tapes on a password-protected software and
stored on a secure Yale server.
To protect your confidentiality, all recordings will be coded by number, and these codes
will be stored on password-protected databases on encrypted computers.
All video/audio recordings used in the study will be kept for 10 years after data analysis
has concluded. Recordings will then be destroyed in accordance with HIPAA
requirements.
I agree that video/audio recordings may be taken of me as part of the study entitled:
Video Cognitive Behavioral Therapy to Prevent Depression in Patients with
Inflammatory Bowel Disease
The films may be used for (Check all that apply)
a. ________ any purpose relevant to research, medical evaluation, training
b. ________ purposes of the study only
If seeking permission to retain tapes for future use: You have the choice of how long we
may keep your tapes.
a. ______My tapes may be kept permanently for research, educational or
training purposes.
b. _____ My tapes must be destroyed after completion of study.
I understand that my consent for this part of the study is optional, and I am free to refuse
this request and still participate in the study. I understand that I may request at any time
during the research that the videotapes or films of me be destroyed and the research staff
will honor my request promptly. My signature below indicates my consent for the use of
these tapes.
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__________________________
Signature of Subject

___________________
Date

__________________________
Person Obtaining Consent

___________________
Date
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Appendix C: CBT Content
Week

1

Theme
Education about IBD and
introduction to the
program

2

Stress and relaxation

3

Automatic thoughts and
cognitive distortions

4

Cognitive restructuring

5

Exposure and overcoming
avoidance

6

Coping strategies

7

Assertiveness training
Relationships and
communication

8
9
10

Activities

Attention and distraction
Maintaining good mental
health

Video materials about IBD in general and diet in IBD; goal setting
What is stress--its physiology, fight or flight response, symptoms
of stress, observe yourself in stressful situations; relaxation
training--4 voice recorded sessions of relaxation exercises
Thinking, feeling and behavior--introducing CBT basic concepts,
observe your thoughts and feelings, identify core beliefs; another
2 recordings to practice relaxation
Emotional wellbeing, appraisal of mood, automatic thought-identify and challenge them
Avoidance and conditioning--how do we learn to be afraid and
how do we overcome conditioning; desensitization and another 2
records of relaxation skill building
What is coping, how do we cope with stress and IBD; worry and
sleep; relaxation to help you sleep
Taking responsibility; introducing assertiveness in communication
with family and health professionals; learning to say no
Social support--quality and quantity; maintaining social networks
and interests when dealing with IBD; communication strategies
Techniques to manage IBD-related pain and discomfort--imagery,
focus, distraction
Keeping up momentum--how not to forget what you have learnt;
review old goals and plan new ones

Appendix D: Schedule of Assessments

Assessment

Week 24

Week of Intervention

Baseline
HADS

x

1
x

2
x

3
x

4
x

5
x

6
x

7
x

8
x

9
x

10
x

11
x

12
x

x

SF-12

x

x

x

x

x

x

x

x

x

x

x

x

x

x

CBC

x

x

x

ESR

x

x

x

CRP

x

x

x

Fecal Calprotectin

x

x

x

SES-CD

x

x

UC Mayo

x

x
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Appendix E: Hospital Anxiety and Depression Scale (HADS)
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Appendix F: 12-Item Short Form Survey (SF-12)
SF-12 Health Survey
This survey asks for your views about your health. This information will help keep track of how you feel and how
well you are able to do your usual activities. Answer each question by choosing just one answer. If you are
unsure how to answer a question, please give the best answer you can.

1. In general, would you say your health is:

□ 1 Excellent

□ 2 Very good
□ 3 Good
□ 4 Fair
□ 5 Poor
The following questions are about activities you might do during a typical day. Does your health now
limit you in these activities? If so, how much?
YES,
limited
a lot

YES,
limited
a little

NO, not
limited
at all

2. Moderate activities such as moving a table, pushing
□1
□2
□3
a vacuum cleaner, bowling, or playing golf.
3. Climbing several flights of stairs.
□1
□2
□3
During the past 4 weeks, have you had any of the following problems with your work or other regular
daily activities as a result of your physical health?
YES
NO
4. Accomplished less than you would like.
□1
□2
5. Were limited in the kind of work or other activities.
□1
□2
During the past 4 weeks, have you had any of the following problems with your work or other regular
daily activities as a result of any emotional problems (such as feeling depressed or anxious)?
YES
NO
6. Accomplished less than you would like.
□1
□2
7. Did work or activities less carefully than usual.
□1
□2
8. During the past 4 weeks, how much did pain interfere with your normal work (including work outside
the home and housework)?

□ 1 Not at all

□ 2 A little bit
□ 3 Moderately
□ 4 Quite a bit
□ 5 Extremely
These questions are about how you have been feeling during the past 4 weeks.
For each question, please give the one answer that comes closest to the way you have been feeling.
How much of the time during the past 4 weeks…

9. Have you felt calm & peaceful?
10. Did you have a lot of energy?
11. Have you felt down-hearted and

All of
the
time

Most
of the
time

A good
bit of
the time

Some
of the
time

A little
of the
time

None
of the
time

□1
□1
□1

□2
□2
□2

□3
□3
□3

□4
□4
□4

□5
□5
□5

□6
□6
□6

blue?
12. During the past 4 weeks, how much of the time has your physical health or emotional problems
interfered with your social activities (like visiting friends, relatives, etc.)?

□ 1 All of the time □ 2 Most of the time

□ 3 Some of the time

□ 4 A little of the time

□ 5 None of the time

Patient name:
Date:
PCS:
MCS:
________________________ _____________________ ________________________ _____
Visit type (circle one)
Preop

6 week

3 month

6 month

12 month
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24 month

Other:_________

Appendix G: Simple Endoscopic Score for Crohn’s Disease (SES-CD)
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Appendix H: Mayo Score for Ulcerative Colitis
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Appendix I: Sample Size Calculation

G*Power Version 3.1.9.6
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